I-mab Stock News

Zacks Investment Research downgraded shares of I-Mab (NASDAQ:IMAB) from a buy rating to a hold rating in a report published on Monday, Zacks.com reports. According to Zacks, I-Mab is a clinical stage biopharmaceutical company. It engages in discovery, development and commercialization of biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune [] The post Zacks Investment Research Downgrades I-Mab (NASDAQ:IMAB) to Hold appeared first on ETF Daily News .

I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient had been dosed in the I-Mab and Nhwa-sponsored U.S. Phase I study of Protollin, an investigational drug being co-developed to treat Alzheimers disease. []

I-Mab (NASDAQ:IMAB) has been assigned an average rating of Buy from the eight ratings firms that are covering the stock, MarketBeat reports. Eight research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have issued a report on the stock in the last year is $86.00. []

As U.S. Takes Aim At China Drug Makers, Innovators Appear At Biggest Risk

I-Mab (NASDAQ:IMAB) shares, rose in value on Wednesday, 12/15/21, with the stock price down by -4.92% to the previous days close as strong demand from buyers drove the stock to $46.97. Actively observing the price movement in the last trading, the stock closed the session at $49.40. Referring to stocks 52-week performance, its high was What Analysts Were Expecting After I-Mab (NASDAQ: IMAB) fell -4.92% Read More »

I-Mab (NASDAQ:IMAB) gapped down before the market opened on Tuesday . The stock had previously closed at $51.20, but opened at $49.06. I-Mab shares last traded at $47.75, with a volume of 7,656 shares changing hands. A number of research firms have weighed in on IMAB. Needham & Company LLC upped their price target on []

Zacks Investment Research upgraded shares of I-Mab (NASDAQ:IMAB) from a hold rating to a buy rating in a research report sent to investors on Friday, Zacks.com reports. Zacks Investment Research currently has $61.00 price target on the stock. According to Zacks, I-Mab is a clinical stage biopharmaceutical company. It engages in discovery, development and commercialization []

Zacks Investment Research upgraded shares of I-Mab (NASDAQ:IMAB) from a hold rating to a buy rating in a report published on Friday, Zacks.com reports. The firm currently has $61.00 price objective on the stock. According to Zacks, I-Mab is a clinical stage biopharmaceutical company. It engages in discovery, development and commercialization of biologics to treat []

Shares of I-Mab (NASDAQ:IMAB) gapped down prior to trading on Monday . The stock had previously closed at $57.43, but opened at $52.73. I-Mab shares last traded at $52.05, with a volume of 2,387 shares traded. A number of analysts have commented on IMAB shares. Needham & Company LLC raised their price objective on I-Mab []

I-Mab (NASDAQ:IMAB) concluded the trading at $52.75 on Friday, December 03 with a fall of -8.15% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $57.43 with its price kept floating in the range of $51.83 and $57.25 on the day. Considering I-Mab (IMAB) Could Be Possessing A Gold Mine Read More »

Shares of I-Mab (NASDAQ:IMAB) have received an average rating of Buy from the seven analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month target price among brokers that have issued []

I-Mab (NASDAQ:IMAB) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued to clients and investors on Thursday, Zacks.com reports. According to Zacks, I-Mab is a clinical stage biopharmaceutical company. It engages in discovery, development and commercialization of biologics to treat diseases with significant unmet medical []

Vanguard Group Inc. bought a new stake in shares of I-Mab (NASDAQ:IMAB) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 59,348 shares of the companys stock, valued at approximately $4,982,000. Vanguard Group Inc. owned approximately 0.08% of I-Mab at the end []